The deadlines for major milestones in TB control are drawing near. After decades of concerted efforts and dedicated investment, the global health community plans to reach 40 million people with TB treatment by 2025. But, the COVID-19 response in low- and middle-income countries will build on the same infrastructure currently serving TB, particularly health facilities, laboratories, human resources and community-based resources. How do we deploy a COVID-19 response while preserving the gains against TB?
Dr. Madhukar Pai , Professor and Canada Research Chair of Epidemiology and Global Health, McGill University and Director, McGill International TB Centre
Dr. Norbert Ndjeka, Director, Drug-Resistant TB, TB and HIV, National Department of Health, South Africa
Dr. Lisa Stevens , Scientist and Senior Technical Advisor, TB, FHI 360